BackgroundBone mineral density and proteins/peptides determination in blood and urine as markers of bone resorption and formation are currently used to diagnose osteoporosis (OP) and metabolic bone diseases. However, these methods have some disadvantages for bone turnover evaluation. Recent evidence suggests that in RA changes in the secretion of hormones of white adipose tissue can be revealed [1,2]. One of them is Adiponectin possessing anti-inflammatory, anti-diabetic and anti-atherogenic properties. Changes in Adiponectin levels may reflect influence of immune inflammation on bone turnover.ObjectivesTo study the clinical and diagnostic value of serum Adiponectin determination in RA patients complicated by OP.MethodsWe examined 88 women with documented diagnosis of RA and mean disease duration of 6.56±0.88 years. We used EULAR/ARA 2010 criteria to diagnose the patients. Female patients with II degree of disease activity (DAS28), Steinbrocker stage II (erosive), rheumatoid factor- and anti-cyclic-citrullinated peptide antibody-positive were prevalent. We excluded patients who had surgery or developed an infection within the last 8 weeks, pregnant and breast-feeding women, those with severe heart, liver or kidney disease, immune deficiency, leukopenia or chronic infection.A control group of 45 healthy females aged of 25 and 59 years were included in the study. There were no reported findings of joint pain and RA symptoms in the group. The groups were adjusted for age (p>0.05) and showed no statistically significant differences.We measured serum Adiponectin levels (μg/ml) using Human Adiponectin ELISA commercial test systems (BioVendor, Czech Republic, cat No. RD195023100). We used spectrophotometer with wavelength of 450 nm to detect the test results (“Multiskan” immunoenzyme analyzer, Finland). We plotted a curve using computer software. We diagnosed OP using dual-energy X-ray absorptiometry with LUNAR DPX PRO (GE, USA).ResultsSerum adiponectin levels in the control group were 12.5±0.9 μg/ml (M±m). Adiponectin levels in healthy subjects measured as M ±2d, ranged between 0.44 and 24.56 μg/ml. Patients with OP and RA had significantly higher levels of serum Adiponectin (p<0.001). Mean serum Adiponectin levels in RA patients who had normal bone density and had no OP were 35.21±0.6 μg/ml. Mean serum Adiponectin levels in RA/OP patients with low bone mineral density were 52.42±0.69 μg/ml. Adiponectin levels of 44 μg/ml and higher were associated with osteoporosis. Adiponectin levels of 43.9 μg/ml and lower were associated with normal bone density.ConclusionsThus, we revealed that Adiponectin levels depend on osteoporosis presence in RA patients. We suppose that Adiponectin determination may be useful laboratory marker for OP diagnosis. The test may be used to reduce the risk of low-energy fractures and to improve the quality of life in RA.ReferencesEliseev M.S. Revmatoidnyj artrit na Kongresse EULAR-2014 v Parizhe: novye zadachi, novye perspektivy. Revmatologija. 2014;5(16):s.2–5.Polyakova J. V., Simakova E. S., Zavo...

Objective. To study the effect of peloids Saki Lake and brine, combined with the drug “Berlition® 600” on immunoregulatory processes based on morphological and functional changes of the skin in patients with plaque psoriasis. Materials and methods. The study involved 90 patients with plaque psoriasis mild to moderate severity. The study group included - 45 patients receiving therapeutic mud treatments, and the brine baths in conjunction with the “Berlition® 600” in the control group - 45 patients treated with mud baths and RPMA. All patients using flow cytometry laser defined subpopulations of T-lymphocytes. The concentration of Ig A, M and G in the blood was determined by mikroturbidimetricheskim with monospecific antisera; proinflammatory and anti-inflammatory cytokines (IL-1a, IL-2, IL-8, IL-10, TNF-α) was measured by enzyme-linked immunosorbent assay (ELISA). Immunohistochemistry Skin biopsy were studied with the definition of CD3+, CD4+, CD8+ T-lymphocytes. Results and discussion. Patients in both treatment groups revealed an imbalance of T and B-cell immunity to the reduction in the number of helper-inductor (CD4+) and cytotoxic (CD8+) subpopulations of T-L in peripheral blood and increase in CD3+, with a predominance of CD8+ in psoriatic infiltrate amid overproduction of cytokines. Procedures for medical mud and the brine baths in combination with the drug “Berlition® 600” has a marked immunomodulatory effect due normalitsatsiey of T-cell immunity and reduction of the balance of cytokine profile, “clinical cure” and “significant improvement” reached 45 (100%) patients, the index regression PASI- 96,7 ± 1,3% DLQI-86 ± 2,1%. Conclusions. Peloids, balneotherapy in Lake Saki in combination with the drug “Berlition® 600” has a high clinical efficacy due to immunomodulatory, antiproliferative and anti-inflammatory effects and can be recommended as a differentiated, immunomodulatory therapy in patients with plaque psoriasis mild to moderate severity.

The article outlines the questions of pathogenesis of acne as well as clinical trial data, which indicate that the skin of patients with acne needs comprehensive care with therapeutic cosmetics. Long term use of medical cosmetics has a positive effect on the course of acne disease. The basis of the study is the use of cosmetics line A “Skinormil” including the patented complex Citobiol lRIS, zinc sulfate and vitamin A. Seventy-four patients with acne of the first, second and third severity were monitored and it was recommended them a comprehensive skin care with medical cosmetics. According to the analysis of the clinical picture, it was concluded that on the background of proper care, there is a positive dynamics in the course of acne.

BackgroundThere are some data indicating that statins produce a pleiotropic effect and can increase bone mineral density. It is also known that some statins (pravastatin, simvastatin) have an anti-inflammatory effect. Simvastatin has been shown to be effective in the treatment of rheumatoid arthritis (RA) in humans. We failed to find any research data indicating that atorvastatin has anti-inflammatory effects.ObjectivesTo study the effect of Atorvastatin on the dynamics of bone mineral density and inflammatory markers of osteoporosis (OP) in patients with RA.MethodsWe examined 170 RA patients aged 22 – 75 years (128 females (75.3%) and 42 males (24.7%)). Bone mineral density was measured with dual-energy X-ray absorptiometry (DEXA) (Lunar DPX-Pro, GE, USA). Additionally, we measured serum osteocalcin levels and urine CrossLaps with ELISA test.We divided the patients into two groups to study the effectiveness of Atorvastatin in the treatment of patients with RA/OP and osteopenia. Group 1 included 38 individuals who received Atorvastatin for 6 months at a dose of 20–40 micrograms per day. The experimental group included 29 patients with OP and osteopenia. They received calcium supplements at a dose of 1000 mg per day.ResultsWe revealed that 84 (51.5%) out of 170 patients with RA had significantly lower Z- and T-scores values. We noted that 17 (20.2%) patients were diagnosed as having osteoporosis, while 67 (79.8%) had osteopenia. The most common manifestations of OP in RA patients included fractures, bone and back pain, as well as decreased muscle strength.We measured biochemical markers of bone turnover at baseline and after 6-month of the treatment. There was significant positive dynamic of clinical and laboratory parameters during a 6-month treatment with Atorvastatin in OP patients with RA. In this patients we observed BMD and muscle strength increasing, reducing of bone and back pain, decreasing of C-reactive protein. Urinary CrossLaps were significantly decreased. Atorvastatin was well tolerated. There were few of insignificant side effects which were reduced after the drug dose decreasing. Symptomatic improvement occurred within 2–3 months after starting of atorvastatin therapy. Second group patients who received calcium monotherapy showed signs of progressive OP: bone mineral density continued to decrease (mean -2.7±0.18%), while bone pain and biochemical markers of bone metabolism remained unchanged.ConclusionsWe concluded that Atorvastatin may be used in the treatment of RA patients and can help to stabilize bone mineral density and improve the OP symptoms.Disclosure of InterestNone declared